Dr. Sanjay R. Mohan

Emergency Medicine
111 Broadway, 
New York, NY 
9 Years of Experience
111 Broadway, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sanjay Mohan is an Emergency Medicine provider in New York, New York. Dr. Mohan has been practicing medicine for over 9 years and is rated as an Experienced provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Myeloproliferative Neoplasms (MPN), Mast Cell Activation Syndrome (MCAS), Aseptic and Alopecic Nodules of Scalp (AANS), and Nephrectomy.

His clinical research consists of co-authoring 68 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2016
Specialties
Emergency Medicine
Licenses
Emergency Medicine in NY
Hospital Affiliations
Nyu Langone Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

NEW YORK UNIVERSITY
111 Broadway, New York, NY 10006

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Ruxolitinib in Treatment-naïve Patients With Myelofibrosis
A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Ruxolitinib in Treatment-naïve Patients With Myelofibrosis
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Other, Drug
Study Drugs: Selinexor, Ruxolitinib
Study Phase: Phase 3
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: KPT-8602
Study Phase: Phase 1/Phase 2
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 17, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
View 3 Less Clinical Trials

68 Total Publications

Biostatistics and Epidemiology for the Toxicologist: Miscellaneous Bias - Confirmation, Non-Response, Survivorship, and Selection.
Biostatistics and Epidemiology for the Toxicologist: Miscellaneous Bias - Confirmation, Non-Response, Survivorship, and Selection.
Journal: Journal of medical toxicology : official journal of the American College of Medical Toxicology
Published: May 13, 2025
Similar Doctors
Experienced in Myeloproliferative Neoplasms (MPN)
Dr. Binita R. Shah
Emergency Medicine
Experienced in Myeloproliferative Neoplasms (MPN)
Dr. Binita R. Shah
Emergency Medicine
450 Clarkson Ave, 
Brooklyn, NY 
 (5.0 miles away)
718-245-4790
Languages Spoken:
English
See accepted insurances

Binita Shah is an Emergency Medicine provider in Brooklyn, New York. Dr. Shah is rated as an Advanced provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). Her top areas of expertise are Myeloproliferative Neoplasms (MPN), Percutaneous Coronary Intervention (PCI), and Aortic Valve Replacement.

Experienced in Myeloproliferative Neoplasms (MPN)
Dr. John N. Chafos
Family Medicine | Emergency Medicine
Experienced in Myeloproliferative Neoplasms (MPN)
Dr. John N. Chafos
Family Medicine | Emergency Medicine

Family Care PA

257 Route 22 E, 
Green Brook, NJ 
 (26.4 miles away)
732-968-7878
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients

John Chafos is an Emergency Medicine provider in Green Brook, New Jersey. Dr. Chafos is rated as an Advanced provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Vitamin B12 Deficiency, Vitamin D Deficiency, Eyelid Bump, and Muscle Spasms. Dr. Chafos is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mohan's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile